{{Rsnum
|rsid=17884712
|Gene=CYP2C19
|Chromosome=10
|position=96535246
|Orientation=plus
|ReferenceAllele=G
|MissenseAllele=A
|GMAF=0.003214
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
The [[rs17884712]](A) allele defines the [[CYP2C19]] variant known as CYP2C19*9, which is associated with a slight decrease in the metabolism of S-mephenytoin (at least in vitro).{{PMID|12464799}}

{{PharmGKB
|RSID=rs17884712
|Name_s=CYP2C19:431G>A; R144H
|Gene_s=CYP2C19
|Feature=Exon/NonSyn
|Evidence=PubMed ID:12464799
|Annotation=This variant is the defining SNP for CYP2C19*9 and associated with a modest decrease in the V(max) for 4'-hydroxylation of S-mephenytoin in vitro.
|Drugs=mephenytoin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162355682
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}